valeant pharmaceuticals

J.P. Morgan is out with its report today on Valeant Pharmaceuticals (NYSE: VRX), raising its PT from $46 to $53. In a note to clients, J.P. Morgan writes, "Valeant reported solid 1Q/11 results driven by upside from the US dermatology franchise as well as better-than-expected gross margins and...

Piper Jaffray has raised the price target on Valeant Pharmaceuticals (NYSE: VRX) from $62 to $65 and maintains its Overweight rating.

Piper Jaffray has raised the price target on Valeant Pharmaceuticals (NYSE: VRX) from $46 to $62 and maintains its Overweight rating.

J.P. Morgan is out with its report today on Valeant Pharmaceuticals (NYSE: VRX), raising its PT from $44 to $46. In a note to clients, J.P. Morgan writes, "We remain Overweight on VRX shares. Through its business development growth model and favorable tax structure compared to its competitors, we...

Jefferies has issued an update on Valeant Pharmaceuticals (NYSE: VRX). According to Jefferies, "In this note, we provide our periodic review of Valeant's overall business. We see no major flaws and continue to expect upside to numbers from both the existing business as well as future accretive...

Jefferies is out with its report today on Valeant Pharmaceuticals (NYSE: VRX), maintaining Buy. In a note to clients, Jefferies writes, "VRX has been the top performing Spec Pharma stock in 2011 (~40% YTD), but with a high degree of confidence in management's ability to execute on its growth...

Piper Jaffray is out with its report today on Valeant Pharmaceuticals (NYSE: VRX), raising its price target from $41 to $43. In a note to clients, Piper Jaffray writes, "VRX bolsters Central/Eastern Europe brand generics presence with PharmaSwiss acquisition. PharmaSwiss operates in 19 countries...

Piper Jaffray has raised the price target on Valeant Pharmaceuticals (NYSE: VRX) from $41 to $43 and maintains its Overweight rating.

Deutsche Bank is out with an update on Valeant Pharmaceuticals (NYSE: VRX) following the FDA's decision to delay VRX's Ezogabine. The FDA cited non-clinical reasons for the delay. In a note to clients, DB writes, "We maintain our 12 month price target of $30, based on 12x our 2012 cash EPS estimate...

Yesterday evening, Valeant Pharmaceuticals International (NYSE: VRX) and GlaxoSmithKline PLC (NYSE: GSK) jointly announced receipt of a Complete Response FDA letter for Potiga (ezogabine/retigabine), an investigational anti-epileptic drug for the adjunctive treatment of partialonset seizure in...

Jefferies & Company has published a research report on Valeant Pharmaceuticals (NYSE: VRX) after having spent some time with company management post 3Q results. In the report, Jefferies writes "Earlier this month, Valeant reported 3Q results that were somewhat complex, with the market...

Wells Fargo has upgraded Valeant Pharmaceuticals Int'l (NYSE: BVF) to Market Perform with a valuation range of $26-$28. Valeant Pharmaceuticals closed Friday at $26.84.